LAG3 抗体
(Lymphocyte-Activation Gene 3 (LAG3))
Lymphocyte-activation protein 3 belongs to Ig superfamily and contains 4 extracellular Ig-like domains. The LAG3 gene contains 8 exons. The sequence data, exon/intron organization, and chromosomal localization all indicate a close relationship of LAG3 to CD4. [provided by RefSeq, Jul 2008].
| Catalog no. | 产品 | 适用 | 宿主 / 克隆类型 | 应用 | 价格和交货时间 |
|---|---|---|---|---|---|
| LAG3 抗体 | 人, 猴 | 小鼠 Monoclonal |
|
|
|
| LAG3 抗体 (N-Term) (Atto 488) | 人 | 小鼠 Monoclonal |
|
|
|
| LAG3 抗体 (N-Term) (Atto 647N) | 人 | 小鼠 Monoclonal |
|
|
|
| LAG3 抗体 (AA 1-360) | 人 | 小鼠 Polyclonal |
|
|
|
| LAG3 抗体 (AA 23-245) | 人 | 兔 Monoclonal |
|
|
|
| LAG3 抗体 (Internal Region) | 人 | 山羊 Polyclonal |
|
|
|
| LAG3 抗体 (PE-Cy5.5) | 人 | 兔 Polyclonal |
|
|
|
| LAG3 抗体 (PE-Cy7) | 人 | 兔 Polyclonal |
|
|
|
| LAG3 抗体 (PE-Cy5) | 人 | 兔 Polyclonal |
|
|
|
| LAG3 抗体 (AA 201-300) (AbBy Fluor® 680) | 人 | 兔 Polyclonal |
|
|
|
| LAG3 抗体 (AA 201-300) (AbBy Fluor® 750) | 人 | 兔 Polyclonal |
|
|
|
| LAG3 抗体 (AA 201-300) (AbBy Fluor® 488) | 人 | 兔 Polyclonal |
|
|
|
| LAG3 抗体 (AA 201-300) (AbBy Fluor® 594) | 人 | 兔 Polyclonal |
|
|
|
| LAG3 抗体 (AA 201-300) (Biotin) | 人 | 兔 Polyclonal |
|
|
|
| LAG3 抗体 (AA 201-300) (AbBy Fluor® 555) | 人 | 兔 Polyclonal |
|
|
|
| LAG3 抗体 (AA 201-300) (AbBy Fluor® 647) | 人 | 兔 Polyclonal |
|
|
|
| LAG3 抗体 (AA 201-300) (AbBy Fluor® 350) | 人 | 兔 Polyclonal |
|
|
|
| LAG3 抗体 (AA 201-300) (Cy5.5) | 人 | 兔 Polyclonal |
|
|
|
| LAG3 抗体 (AA 201-300) (Cy7) | 人 | 兔 Polyclonal |
|
|
|
| LAG3 抗体 (AA 201-300) (HRP) | 人 | 兔 Polyclonal |
|
|
Primary Antibody
- WB (Western Blotting: 所列应用)
- ELISA (ELISA: 所列应用)
- IHC (Immunohistochemistry: 所列应用)
- ICC (Immunocytochemistry: 所列应用)
- IP (Immunoprecipitation: 所列应用)
- Func (Functional Studies: 所列应用)
4 references - 适用
- 人, 猴
- 宿主
- 小鼠
- 克隆形成能力
- Monoclonal
- 克隆
- 11E3
- 标记
- unconjugated
- 抗体亚型
- IgG1
Primary Antibody
- FACS (Flow Cytometry: 有验证图片)
- ICC (Immunocytochemistry: 所列应用)
- 适用
- 人
- 宿主
- 小鼠
- 克隆形成能力
- Monoclonal
- 克隆
- 17B4
- 标记
- Atto 488
- 抗体亚型
- IgG1 kappa
- 抗原表位
- N-Term
Primary Antibody
- FACS (Flow Cytometry: 有验证图片)
- ICC (Immunocytochemistry: 所列应用)
- 适用
- 人
- 宿主
- 小鼠
- 克隆形成能力
- Monoclonal
- 克隆
- 17B4
- 标记
- Atto 647N
- 抗体亚型
- IgG1 kappa
- 抗原表位
- N-Term
Primary Antibody
- WB (Western Blotting: 有验证图片)
- 适用
- 人
- 宿主
- 小鼠
- 克隆形成能力
- Polyclonal
- 标记
- unconjugated
- 抗原表位
- AA 1-360
Primary Antibody
- FACS (Flow Cytometry: 有验证图片)
- ELISA (ELISA: 所列应用)
- 适用
- 人
- 宿主
- 兔
- 克隆形成能力
- Monoclonal
- 克隆
- DM160
- 标记
- unconjugated
- 抗体亚型
- IgG
- 抗原表位
- AA 23-245
Primary Antibody
- WB (Western Blotting: 有验证图片)
- ELISA (ELISA: 所列应用)
- 质量等级
- Verified
- 适用
- 人
- 宿主
- 山羊
- 克隆形成能力
- Polyclonal
- 标记
- unconjugated
- 抗体亚型
- IgG
- 抗原表位
- Internal Region
Primary Antibody
- WB (Western Blotting: 所列应用)
- 适用
- 人
- 宿主
- 兔
- 克隆形成能力
- Polyclonal
- 标记
- PE-Cy5.5
- 抗体亚型
- IgG
Primary Antibody
- WB (Western Blotting: 所列应用)
- 适用
- 人
- 宿主
- 兔
- 克隆形成能力
- Polyclonal
- 标记
- PE-Cy7
- 抗体亚型
- IgG
Primary Antibody
- WB (Western Blotting: 所列应用)
- 适用
- 人
- 宿主
- 兔
- 克隆形成能力
- Polyclonal
- 标记
- PE-Cy5
- 抗体亚型
- IgG
Primary Antibody
- WB (Western Blotting: 所列应用)
- IF (p) (Immunofluorescence (Paraffin-embedded Sections): 所列应用)
- IF (cc) (Immunofluorescence (Cultured Cells): 所列应用)
- 适用
- 人
- 宿主
- 兔
- 克隆形成能力
- Polyclonal
- 标记
- AbBy Fluor® 680
- 抗体亚型
- IgG
- 抗原表位
- AA 201-300
Primary Antibody
- WB (Western Blotting: 所列应用)
- IF (p) (Immunofluorescence (Paraffin-embedded Sections): 所列应用)
- IF (cc) (Immunofluorescence (Cultured Cells): 所列应用)
- 适用
- 人
- 宿主
- 兔
- 克隆形成能力
- Polyclonal
- 标记
- AbBy Fluor® 750
- 抗体亚型
- IgG
- 抗原表位
- AA 201-300
Primary Antibody
- WB (Western Blotting: 所列应用)
- IF (p) (Immunofluorescence (Paraffin-embedded Sections): 所列应用)
- IF (cc) (Immunofluorescence (Cultured Cells): 所列应用)
- 适用
- 人
- 宿主
- 兔
- 克隆形成能力
- Polyclonal
- 标记
- AbBy Fluor® 488
- 抗体亚型
- IgG
- 抗原表位
- AA 201-300
Primary Antibody
- WB (Western Blotting: 所列应用)
- IF (p) (Immunofluorescence (Paraffin-embedded Sections): 所列应用)
- IF (cc) (Immunofluorescence (Cultured Cells): 所列应用)
- 适用
- 人
- 宿主
- 兔
- 克隆形成能力
- Polyclonal
- 标记
- AbBy Fluor® 594
- 抗体亚型
- IgG
- 抗原表位
- AA 201-300
Primary Antibody
- WB (Western Blotting: 所列应用)
- IHC (p) (Immunohistochemistry (Paraffin-embedded Sections): 所列应用)
- IHC (fro) (Immunohistochemistry (Frozen Sections): 所列应用)
- 适用
- 人
- 宿主
- 兔
- 克隆形成能力
- Polyclonal
- 标记
- Biotin
- 抗体亚型
- IgG
- 抗原表位
- AA 201-300
Primary Antibody
- WB (Western Blotting: 所列应用)
- IF (p) (Immunofluorescence (Paraffin-embedded Sections): 所列应用)
- IF (cc) (Immunofluorescence (Cultured Cells): 所列应用)
- 适用
- 人
- 宿主
- 兔
- 克隆形成能力
- Polyclonal
- 标记
- AbBy Fluor® 555
- 抗体亚型
- IgG
- 抗原表位
- AA 201-300
Primary Antibody
- WB (Western Blotting: 所列应用)
- IF (p) (Immunofluorescence (Paraffin-embedded Sections): 所列应用)
- IF (cc) (Immunofluorescence (Cultured Cells): 所列应用)
- 适用
- 人
- 宿主
- 兔
- 克隆形成能力
- Polyclonal
- 标记
- AbBy Fluor® 647
- 抗体亚型
- IgG
- 抗原表位
- AA 201-300
Primary Antibody
- WB (Western Blotting: 所列应用)
- IF (p) (Immunofluorescence (Paraffin-embedded Sections): 所列应用)
- IF (cc) (Immunofluorescence (Cultured Cells): 所列应用)
- 适用
- 人
- 宿主
- 兔
- 克隆形成能力
- Polyclonal
- 标记
- AbBy Fluor® 350
- 抗体亚型
- IgG
- 抗原表位
- AA 201-300
Primary Antibody
- WB (Western Blotting: 所列应用)
- IF (p) (Immunofluorescence (Paraffin-embedded Sections): 所列应用)
- IF (cc) (Immunofluorescence (Cultured Cells): 所列应用)
- 适用
- 人
- 宿主
- 兔
- 克隆形成能力
- Polyclonal
- 标记
- Cy5.5
- 抗体亚型
- IgG
- 抗原表位
- AA 201-300
Primary Antibody
- WB (Western Blotting: 所列应用)
- IF (p) (Immunofluorescence (Paraffin-embedded Sections): 所列应用)
- IF (cc) (Immunofluorescence (Cultured Cells): 所列应用)
- 适用
- 人
- 宿主
- 兔
- 克隆形成能力
- Polyclonal
- 标记
- Cy7
- 抗体亚型
- IgG
- 抗原表位
- AA 201-300
Primary Antibody
- WB (Western Blotting: 所列应用)
- IHC (p) (Immunohistochemistry (Paraffin-embedded Sections): 所列应用)
- IHC (fro) (Immunohistochemistry (Frozen Sections): 所列应用)
- 适用
- 人
- 宿主
- 兔
- 克隆形成能力
- Polyclonal
- 标记
- HRP
- 抗体亚型
- IgG
- 抗原表位
- AA 201-300
Latest Publications for our LAG3 抗体
: "Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers." in: Nature medicine, Vol. 25, Issue 1, pp. 89-94, (2019) (PubMed).
: "Microtubule-Driven Stress Granule Dynamics Regulate Inhibitory Immune Checkpoint Expression in T Cells." in: Cell reports, Vol. 26, Issue 1, pp. 94-107.e7, (2019) (PubMed).
: "Suppression of a broad spectrum of liver autoimmune pathologies by single peptide-MHC-based nanomedicines." in: Nature communications, Vol. 10, Issue 1, pp. 2150, (2019) (PubMed).
: "Diagnostic value of peripheral blood immune profiling in colorectal cancer." in: Annals of surgical treatment and research, Vol. 94, Issue 6, pp. 312-321, (2018) (PubMed).
: "Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1 c259T Cells in Synovial Sarcoma. ..." in: Cancer discovery, Vol. 8, Issue 8, pp. 944-957, (2018) (PubMed).
: "Enhancing the Potency and Specificity of Engineered T Cells for Cancer Treatment." in: Cancer discovery, Vol. 8, Issue 8, pp. 972-987, (2018) (PubMed).
: "Profiling Immune Escape in Hodgkin's and Diffuse large B-Cell Lymphomas Using the Transcriptome and Immunostaining." in: Cancers, Vol. 10, Issue 11, (2018) (PubMed).
: "LAG-3 Represents a Marker of CD4+ T Cells with Regulatory Activity in Patients with Bone Fracture." in: Immunological investigations, Vol. 47, Issue 5, pp. 492-503, (2018) (PubMed).
: "Antitumor effects of the silencing of programmed cell death ligand 1 in colorectal cancer via immunoregulation." in: Oncology reports, Vol. 40, Issue 6, pp. 3370-3380, (2018) (PubMed).
: "Function and regulation of LAG3 on CD4+CD25-T cells in non-small cell lung cancer." in: Experimental cell research, Vol. 360, Issue 2, pp. 358-364, (2017) (PubMed).
: "Microtubule-Driven Stress Granule Dynamics Regulate Inhibitory Immune Checkpoint Expression in T Cells." in: Cell reports, Vol. 26, Issue 1, pp. 94-107.e7, (2019) (PubMed).
: "Suppression of a broad spectrum of liver autoimmune pathologies by single peptide-MHC-based nanomedicines." in: Nature communications, Vol. 10, Issue 1, pp. 2150, (2019) (PubMed).
: "Diagnostic value of peripheral blood immune profiling in colorectal cancer." in: Annals of surgical treatment and research, Vol. 94, Issue 6, pp. 312-321, (2018) (PubMed).
: "Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1 c259T Cells in Synovial Sarcoma. ..." in: Cancer discovery, Vol. 8, Issue 8, pp. 944-957, (2018) (PubMed).
: "Enhancing the Potency and Specificity of Engineered T Cells for Cancer Treatment." in: Cancer discovery, Vol. 8, Issue 8, pp. 972-987, (2018) (PubMed).
: "Profiling Immune Escape in Hodgkin's and Diffuse large B-Cell Lymphomas Using the Transcriptome and Immunostaining." in: Cancers, Vol. 10, Issue 11, (2018) (PubMed).
: "LAG-3 Represents a Marker of CD4+ T Cells with Regulatory Activity in Patients with Bone Fracture." in: Immunological investigations, Vol. 47, Issue 5, pp. 492-503, (2018) (PubMed).
: "Antitumor effects of the silencing of programmed cell death ligand 1 in colorectal cancer via immunoregulation." in: Oncology reports, Vol. 40, Issue 6, pp. 3370-3380, (2018) (PubMed).
: "Function and regulation of LAG3 on CD4+CD25-T cells in non-small cell lung cancer." in: Experimental cell research, Vol. 360, Issue 2, pp. 358-364, (2017) (PubMed).
Aliases for LAG3 抗体
lymphocyte activating 3 (LAG3) 抗体lymphocyte-activation gene 3 (Lag3) 抗体
lymphocyte activating 3 (Lag3) 抗体
CD223 抗体
LAG-3 抗体
Ly66 抗体
您还需要查找其他产品吗？
You are here:
